| Literature DB >> 27561898 |
Jenny Dahlström1, Tiantian Liu2, Xiaotian Yuan3, Leonie Saft4, Mehran Ghaderi4, Ya Bin Wei5, Catharina Lavebratt5, Ping Li6, Chengyun Zheng7, Magnus Björkholm3, Dawei Xu3.
Abstract
The telomerase reverse transcriptase (TERT) gene rs2736100_C allele has recently been shown to be associated with an increased risk for myeloproliferative neoplasms (MPNs) among Caucasians. However, it is unknown if this association is present in other ethnical populations and whether rs2736100 allele frequencies mirror the incidence of MPNs in a population. Here we genotyped TERT rs2736100 variants in 126 Swedish and 101 Chinese MPN patients and their age-, sex-, and ethnically-matched healthy controls. Healthy Chinese adults had a higher frequency of the A allele and lower frequencies of the C allele compared to Swedish counterparts (57.4 vs 47.0 % for A, 42.6 vs 53.0 % for C, P = 0.006). Both Swedish and Chinese patients harbored significantly higher C allele frequency than their controls (62.7 vs 53.0 % and 57.4 vs 42.6 % for Swedish and Chinese, respectively, P = 0.004). Swedes and Chinese bearing the CC genotype had a significantly increased risk of MPN compared to AA carriers (OR = 2.47; 95 % CI: 1.33-4.57, P = 0.003, for Swedes, and OR = 3.45; 95 % CI: 1.52-7.85, P = 0.005, for Chinese). Further analyses showed that rs2736100_CC was associated with robustly enhanced risk in males only (CC vs AA, OR = 5.11; 95 % CI: 2.19-11.92, P < 0.0001). The CC-carrying MPN patients exhibited significantly higher TERT expression than patients with the AC genotype. Collectively, the rs2736100_C is a risk allele for MPNs in Swedish and Chinese males, and the lower incidence of MPNs in the Chinese population is correlated with a lower rs2736100_C risk allele frequency.Entities:
Keywords: Cancer genetics; Myeloproliferative neoplasms; Single nucleotide polymorphism; TERT; Telomerase
Mesh:
Substances:
Year: 2016 PMID: 27561898 PMCID: PMC5040742 DOI: 10.1007/s00277-016-2787-7
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673
Characteristics of healthy controls and patients with MPN
| Sweden | China | |||
|---|---|---|---|---|
| Controls | MPN | Controls | MPN | |
| Number | 756 | 126 | 101 | 101 |
| Age (years) | ||||
| Mean ± SD | 64 ± 5 | 64 ± 14 | 58 ± 15 | 58 ± 15 |
| Median (range) | 64 (54–74) | 65 (25–106) | 60 (17–82) | 60 (17–82) |
| Sex [%females] | 53 | 53 | 50 | 50 |
| MPN subtype, | ||||
| PV | 41 (32.5) | 16 (15.8) | ||
| ET | 40 (31.7) | 38 (37.6) | ||
| PMF | 28 (22.3) | 15 (14.9) | ||
| MPN-NOS | 17 (13.5) | 32 (31.7) | ||
| JAK2-status, | ||||
| JAK2 V617F− | 60 (47.6) | 38 (37.6) | ||
| JAK2 V617F+ | 66 (52.4) | 56 (55.4) | ||
| Unknown | 0 | 7 (7.0) | ||
| CALR mutation | 45 | Unknown | ||
MPN myeloproliferative neoplasm, PV polycythemia vera, ET essential thrombocythemia, PMF primary myelofibrosis
Comparison of genotype distribution of TERT rs2736100 in healthy control populations in Sweden and China
| Sweden | China | |||
|---|---|---|---|---|
|
| N (%) | N (%) |
| |
| Genotype | 756 (100) | 101 (100) | ||
| AC+CC | 589 (77.9) | 68 (67.3) |
| |
| AA | 167 (22.1) | 33 (32.7) | ||
| AA+CC | 379 (50.1) | 51(50.5) | 0.916 | |
| AC | 377 (49.9) | 50 (49.5) | ||
| AA+AC | 544 (72.0) | 83 (82.2) |
| |
| CC | 212 (28.0) | 18 (17.8) | ||
| Allele | A | 711 (47.0) | 116 (57.4) |
|
| C | 801 (53.0) | 86 (42.6) | ||
OR and P-value generated using Fishers' exact test
Significant p-values are shown in italic
Published rs2736100 genotype distributions of healthy populations in China and Europe
| Author | Number | AA (%) | AC (%) | CC (%) | A (%) | C (%) | Area | Reference |
|---|---|---|---|---|---|---|---|---|
| China | ||||||||
| Dahlström et al. | 101 | 33 (32.7) | 50 (49.5) | 18 (17.8) | 116 (57.4) | 86 (42.6) | Northa | This study |
| Yuan et al. | 289 | 86 (29.8) | 144 (49.8) | 59 (20.4) | 316 (54.7) | 262 (45.3) | Northa | [ |
| Wei et al. | 2520 | 814 (32.3) | 1269 (50.4) | 437 (17.3) | 2897 (57.5) | 2143 (42.5) | Southb | [ |
| Total | 2910 | 933 (32.1)* | 1463 (50.3)* | 514 (17.6)* | 3329 (57.2)* | 2491 (42.8)* | ||
| Europe | ||||||||
| Dahlström et al. | 756 | 167 (22.1) | 377 (49.9) | 212 (28.0) | 711 (47.0) | 801 (53.0) | Sweden | This study |
| Jäger et al. | 202 | 47 (23.3) | 88 (43.6) | 67 (33.2) | 182 (45.0) | 222 (55.0) | Italy | [ |
| Krahling et al. | 400 | 111 (27.8) | 188 (47.0) | 101 (25.2) | 410 (51.3) | 390 (48.7) | Hungary | [ |
| Total | 1358 | 325 (23.9)** | 653 (48.0)** | 380 (28.1)** | 1303 (48.0)** | 1413 (52.0)** | ||
| AA vs AC + CC | AC vs AA + CC | CC vs AA + AC | C vs A | |||||
|
| <0.001 | 0.106 | <0.001 | <0.001 | ||||
OR and P value were generated using chi-squared test
aFrom Shandong area
bFrom Shanghai and Guangzhou areas
Comparison of TERT rs2736100 genotypes in MPN patients and healthy controls
|
| Sweden | China | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | MPN | Control | MPN | |||||
|
|
| OR (95 % CI) |
|
|
| OR (95 % CI) |
| |
| All | 756 (100) | 126 (100) | 101 (100) | 101 (100) | ||||
| Alleles | ||||||||
| A | 711 (47.0) | 94 (37.3) | 1.0 (ref) | 116 (57.4) | 86 (42.6) | 1.0 (ref) | ||
| C | 801 (53.0) | 158 (62.7) | 1.49 (1.13-1.96) |
| 86 (42.6) | 116 (57.4) | 1.82 (1.23-2.70) |
|
| Genotypes | ||||||||
| AA | 167 (22.1) | 15 (11.9) | 1.0 (ref) | 33 (32.7) | 17 (16.8) | 1.0 (ref) | ||
| AC | 377 (49.9) | 64 (50.8) | 1.89 (1.05-3.41) |
| 50 (49.5) | 52 (51.5) | 2.02 (1.00-4.08) | 0.057 |
| CC | 212 (28.0) | 47 (37.3) | 2.47 (1.33–4.57) |
| 18 (17.8) | 32 (31.7) | 3.45 (1.52–7.85) |
|
| AA + AC | 544 (72.0) | 79 (62.7) | 1.0 (ref) | 83 (82.2) | 69 (68.3) | 1.0 (ref) | ||
| CC | 212 (28.0) | 47 (37.3) | 1.53 (1.03–2.27) |
| 18 (17.8) | 32 (31.7) | 2.14 (1.11–4.14) |
|
| AC + CC | 589 (77.9) | 111 (88.1) | 1.0 (ref) | 68 (67.3) | 84 (83.2) | 1.0 (ref) | ||
| AA | 167 (22.1) | 15 (11.9) | 0.48 (0.27–0.84) |
| 33 (32.7) | 17 (16.8) | 0.42 (0.21–0.81) |
|
OR and P value were generated using Fishers’ exact test
MPN myeloproliferative neoplasms, OR odds ratio, CI confidence interval
Significant p-values are shown in italic
Genotypes of TERT rs2736100 in men and women
|
| Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | MPN | Control | MPN | |||||
|
|
| OR (95 % CI) |
|
|
| OR (95 % CI) |
| |
| All | 405 (100) | 110 (100) | 452 (100) | 117 (100) | ||||
| A | 385 (47.5) | 73 (33.2) | 1.0 (ref) | 442 (48.9) | 107 (45.7) | 1.0 (ref) | ||
| 425 (52.5) | 147 (66.8) | 1.82 (1.33–2.49) | <0.001 | 462 (51.1) | 127 (54.3) | 1.14 (0.85–1.52) | 0.420 | |
| AA | 87 (21.5) | 7 (6.4) | 1.0 (ref) | 113 (25.0) | 25 (21.4) | 1.0 (ref) | ||
| AC | 211 (52.1) | 59 (53.6) | 3.48 (1.53–7.91) | 0.002 | 216 (47.8) | 57 (48.7) | 1.19 (0.71–2.01) | 0.601 |
| CC | 107 (26.4) | 44 (40.0) | 5.11 (2.19–11.92) | <0.0001 | 123 (27.2) | 35 (29.9) | 1.29 (0.72–2.28) | 0.469 |
| Control | MPN | |||||||
| Men | Women | Men | Women | |||||
| AC + CC | 318 (78.5) | 339 (74.3) | 1.0 (ref) | 103 (93.6) | 92 (78.6) | 1.0 (ref) | ||
| AA | 87 (21.5) | 113 (25.7) | 0.82 (0.60–1.13) | 0.227 | 7 (6.4) | 25 (21.4) | 0.25 (0.10–0.61) |
|
OR and P value were generated using Fisher’s exact test
OR odds ratio, CI confidence interval
Fig. 1TERT mRNA expression and telomere length in MPN patients with different TERT rs2736100 variants. Total cellular RNA and genomic DNA were extracted from granulocytes derived from Swedish MPN patients harboring different TERT rs2736100 genetic variants. TERT mRNA and telomere length were measured by using qRT-PCR and flow-FISH, respectively. a TERT mRNA expression and (b) telomere length. *P < 0.05